Research programme: metabolic disorders therapeutics - EsperionAlternative Names: ESP 41091
Latest Information Update: 09 Jul 2014
At a glance
- Originator Esperion Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic disorders
Most Recent Events
- 13 Mar 2014 Preclinical trials in Metabolic disorders in USA (PO)